-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the NMPA official website announced the latest announcement that BeiGene's anti-PD-1 antibody tislelizumab (Baizean) has been approved for a new indication
Screenshot source: NMPA official website
Tislelizumab is a humanized IgG4 anti-programmed death 1 (PD-1) monoclonal antibody designed to minimize binding to Fcγ receptors in macrophages
Previously, tislelizumab has been approved for 7 indications in China, including full approval for: 1) in combination with chemotherapy for the treatment of patients with first-line advanced squamous non-small cell lung cancer (NSCLC); 2) in combination with chemotherapy For the treatment of first-line advanced non-squamous NSCLC patients; 3) for the treatment of second- or third-line locally advanced or metastatic NSCLC patients with disease progression after previous platinum-containing chemotherapy